SAVIMS

SAVIMS logo white
Menu

Vaccine effectiveness

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19 Vaccines: A New Perspective on Efficacy

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Beattie, K. A. (2022). Worldwide Bayesian causal impact analysis of vaccine administration on deaths and cases associated with COVID-19: A big data analysis of 145 countries. Steve Kirsch’s Substack. Retrieved from https://stevekirsch.substack.com/p/new-big-data-study-of-145-countries Summary: A recent study by Kyle A. Beattie, titled “Worldwide Bayesian Causal Impact Analysis of Vaccine Administration on Deaths and Cases Associated […]

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Impact of COVID-19 Vaccination on Alpha and Delta Variants

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Eyre, D. W., Taylor, D., Purver, M., Chapman, D., Fowler, T., Pouwels, K. B., Walker, A. S., & Peto, T. E. A. (2022). Effect of COVID-19 vaccination on transmission of alpha and delta variants. New England Journal of Medicine, 386(8), 744-756. https://doi.org/10.1056/NEJMoa2116597 Summary: This study investigates the effect of COVID-19 vaccinations on the transmission

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Investigating the Vaccine: Efficacy, Adverse Effects, and Mandates

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Epoch Times. (2022). Special report: Investigating the vaccine: Exploring vaccine efficacy, adverse effects, and making sense of mandates. Epoch Insight, Week 34. Summary: The Epoch Times’ special report delves into the COVID-19 vaccines, revealing concerns regarding their efficacy and safety. It discusses data indicating that vaccinated individuals may represent a higher proportion of COVID-19

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Duration of mRNA Vaccine Protection Against SARS-CoV-2 Omicron Variants in Qatar

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., Al-Thani,

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Transmission Dynamics of SARS-CoV-2 Omicron Variant in Danish Households

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Lyngse, F. P., Mortensen, L. H., Denwood, M. J., Christiansen, L. E., Møller, C. H., Skov, R. L., … & Krause, T. G. (2021). SARS-CoV-2 Omicron VOC transmission in Danish households. medRxiv. https://doi.org/10.1101/2021.12.27.21268278 Summary: This study investigates the transmission of the Omicron variant of SARS-CoV-2 within Danish households, comparing it to the Delta variant.

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

The Omicron Variant and the Vaccine Booster Debate

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Khan, N. A., Al-Thani, H., & El-Menyar, A. (2022). The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues. Travel Medicine and Infectious Disease, 45, 102246. https://doi.org/10.1016/j.tmaid.2021.102246 Summary: The emergence of the Omicron variant of SARS-CoV-2 has sparked global concern due to its high mutation rate and potential

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Increasing Epidemiological Relevance of Vaccinated Individuals in COVID-19 Transmission

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Kampf, G. (2021). The epidemiological relevance of the COVID-19-vaccinated population is increasing. The Lancet Regional Health – Europe, 11, 100272. https://doi.org/10.1016/j.lanepe.2021.100272 Summary: High COVID-19 vaccination rates were anticipated to diminish SARS-CoV-2 transmission; however, recent findings suggest the opposite. In the UK, secondary attack rates among household contacts exposed to fully vaccinated individuals were similar

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Understanding RRR and ARR in Vaccine Trials

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Reference: Iriarte, I., & Phoenix, S. (2021). Understanding relative risk reduction (RRR) and absolute risk reduction (ARR) in vaccine trials. PANDA. https://www.pandata.org/understanding-relative-risk-reduction-and-absolute-risk-reduction-in-vaccine-trials/ Summary: The article discusses the critical distinctions between Relative Risk Reduction (RRR) and Absolute Risk Reduction (ARR) in the context of vaccine trials, particularly those for COVID-19. RRR compares the efficacy of one

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Efficacy and Safety of BNT162b2 mRNA Covid-19 Vaccine at 6 Months

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. The New England Journal of Medicine, 385(19), 1761-1773. https://doi.org/10.1056/NEJMoa2110345 Summary: The BNT162b2 mRNA vaccine demonstrates high efficacy and safety against Covid-19,

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Safety and Efficacy of BNT162b2 mRNA Covid-19 Vaccine through 6 Months

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine, 385(19), 1761-1773. https://doi.org/10.1056/NEJMoa2110345 Summary: The article investigates the safety and efficacy of the BNT162b2 mRNA Covid-19

Scroll to Top